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Abstract
Background: Rotavirus is the most common cause of gastroenteritis in young children worldwide. The aim of the
study was to assess the health outcomes and the economic impact of a universal rotavirus vaccination programme
with RotaTeq, the pentavalent rotavirus vaccine, versus no vaccination programme in Spain.
Methods: A birth cohort was followed up to the age of 5 using a cohort model. Epidemiological parameters were
taken from the REVEAL study (a prospective epidemiological study conducted in Spain, 2004-2005) and from the
literature. Direct and indirect costs were assessed from the national healthcare payer and societal perspectives by
combining health care resource utilisation collected in REVEAL study and unit costs from official sources. RotaTeq
per protocol efficacy data was taken from a large worldwide rotavirus clinical trial (70,000 children). Health
outcomes included home care cases, General Practioner (GP)/Paediatrician, emergency department visits,
hospitalisations and nosocomial infections.
Results: The model estimates that the introduction of a universal rotavirus vaccination programme with RotaTeq
(90% coverage rate) would reduce the rotavirus gastroenteritis (RVGE) burden by 75% in Spain; 53,692 home care
cases, 35,187 GP/Paediatrician visits, 34,287 emergency department visits, 10,987 hospitalisations and 2,053
nosocomial infections would be avoided. The introduction of RotaTeq would avoid about 76% of RVGE-related
costs from both perspectives: €22 million from the national health system perspective and €38 million from the
societal perspective.
Conclusions: A rotavirus vaccination programme with RotaTeq would reduce significantly the important medical
and economic burden of RVGE in Spain.
Background
Acute Gastroenteritis (AGE) is a common disease
among children in both developed and developing coun-
tries, with rotavirus as the principal etiologic agent[1,2].
As it is a highly contagious virus, almost all children
will suffer from paediatric rotavirus gastroenteritis
(RVGE) before 5 years of age[3]. Verstraeten et al[4]
estimated that 4.5 million episodes of RVGE occur each
year in the European Union among children up to 5
years old. The classical symptoms of the disease are
diarrhoea, vomiting and fever[5].
Although death due to RVGE is rare in developed
countries, there is an important morbidity related to the
disease as well as a substantial economic burden asso-
ciated with its management[6]. RVGE is a major reason
for hospitalisation, and it is responsible for an important
number of nosocomial infections in paediatric wards,
which increase the medical resources required for treat-
ing these children with RVGE[7,8]. According to Gil et
al[3], the annual incidence of hospital admissions attri-
butable to rotavirus is 1.0 per 1000 children ≤5y e a r s ,
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years during the winter season. Overall, these authors
estimated that the annual number of days of hospitalisa-
tion attributable to rotavirus exceeds 8,700 in Spain.
Another important consequence of the disease is the
workdays lost by parents and caregivers[9,10]. This has
been estimated to account for 75% of total costs of
RVGE in a primary care setting in Italy[11]. Recent pub-
lications in different European countries have added
information about the burden and costs of the disease
as well as the potential benefits of a universal vaccina-
tion programme[9,12-19].
An oral, pentavalent rotavirus vaccine (RotaTeq),
which has recently been licensed in Europe, has been
shown to be highly efficacious and safe in a large-scale
phase III trial (Rotavirus Efficacy Safety Trial; REST)
[20]. This vaccine offers protection against G1, G2, G3,
G4 and P[8] serotypes, which are responsible for 98% of
all RVGE episodes[21] in Europe, and is available in
Spain. Several published studies have suggested that
effective rotavirus immunisation would provide large
health and economic benefits in Europe[22,23]; however,
no specific data about the potential benefits of a univer-
sal rotavirus vaccination programme in Spain were avail-
able until now. The objective of this study was to assess
the potential health and economic benefits of a universal
vaccination with a pentavalent rotavirus vaccine (Rota-
Teq) from the National Health System (NHS) and socie-
tal perspectives in the Spanish setting using a modelling
approach. The present study is not a cost-effectiveness
analysis.
Methods
Model design
A health-economic cohort model was developed to
assess the costs and health benefits of a universal rota-
virus vaccination programme with RotaTeq versus no
rotavirus vaccination programme by simulating the flow
of a hypothetical cohort of infants from birth to 5 years.
Under each scenario, children may experience or not a
RVGE episode, which may be either community or hos-
pital acquired. When community cases occurred,
patients may seek medical attention either at a primary
care centre (PCC), at an emergency room (ER) or at
hospital. Also, patients may not seek medical attention
and only require home care. Hospital acquired episodes
(nosocomial infections) were assumed to require addi-
tional days of hospitalisation. The “vaccination strategy”
arm included children receiving and not receiving the
vaccine with a coverage rate of 90%[24]. The structure
of the decision model is shown in Figure 1.
Based on incidence data, each children was at risk of
RVGE with corresponding resource consumption and
costs, which were obtained from different sources: the
Rotavirus Gastroenteritis Epidemiology and Viral
Types Accounting for Losses in Public Health and
Society (REVEAL) epidemiological study[25], the
REVEAL costs study[26], the Rotavirus Efficacy &
Safety Trial (REST)[20], national statistics[27], and
from an extensive literature review[28-35]. A discount
rate of 3% was applied to both costs and benefits
based on results from recent Spanish pharmacoeco-
nomic studies[36,37].
Figure 1 Model tree overview - Rotavirus vaccination program versus no Rotavirus vaccination program. PRG: Paediatric Rotavirus
Gastroenteritis (RVGE)
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Epidemiological data
Epidemiological data for patients seeking medical atten-
tion were obtained from the REVEAL study[25], which
was the first European-wide epidemiological study about
rotavirus, specifically conducted to measure epidemiolo-
gical consequences and the burden of RVGE. This pro-
spective, multicenter, observational study on children up
to 5 years old with AGE was performed between Octo-
ber 2004 and September 2005 in seven European coun-
tries including Spain. In Spain, two hospitals, three ERs
and twenty-three PCCs participated in the study and a
total of 801 children were included. A total of 252 of
the 772 stool samples analysed for the presence of rota-
virus, by an ELISA test, were positive (32.6%). A ques-
tionnaire was completed for each child included to
collect data on resource utilisation (consultations, hospi-
talisations, drug consumption, clinical services, extra
childcare, transportation and additional nappies) and
number of parental workdays lost. These data were used
to estimate annual incidence rates of RVGE consulta-
tions at hospital, ER and PCC, and to evaluate the
impact of RVGE on the health care system (health care
consumption) and the society (productivity loss).
Based on the REVEAL study[25], the annual incidence
rates for hospitalisations, ER and PCC consultations in
patients with RVGE seeking medical attention were
6.5/1,000, 18.9/1,000 and 21.9/1,000, respectively. Age-
specific incidences were calculated for seven age groups
(0-3 months, 3-6 months, 6-12 months, 1-2 years, 2-3
years, 3-4 years and 4-5 years) by deriving annual inci-
dences with the specific age group distribution obtained
from REVEAL study.
The proportion of children with RVGE who did not
seek medical care was estimated to be 41.4%. As such
data is not available for Spain; this estimate was taken
from the incidence observed in a study preformed in a
daycare centre in France (Lyon)[33].
The age group distribution for children who did not
seek medical care was assumed to be similar to the one
observed in children visiting a PCC estimated in the
REVEAL study[25].
The incidence of nosocomial infection in children up
to 5 years used in the model was 1.6/1,000[29]. The age
group distribution was derived from the percentages
reported from Gleizes et al[29] and Forster et al[38].
The average extra length of stay due to nosocomial
infections was assumed to be 2.4 days based on the
average results from two Spanish publications[30,31].
According to the Spanish National Statistics Institute
for 2004 (INE)[27], the annual number of births in
Spain was 441,283 and life expectancy was 78.7 years
(average for males and females, year 1998). UNICEF[28]
has reported a mortality rate for children under 5 years
in Spain of 4/1,000. The epidemiological parameters for
the model are shown in Table 1.
Vaccine parameters
The efficacy and safety of the pentavalent rotavirus vac-
cine (RotaTeq) have been demonstrated in the REST
trial[20], a large-scale, double-blind, placebo controlled,
randomised international trial conducted from 2001 to
2004 in 11 different countries which included 70,301
healthy infants aged between 6 and 12 weeks. Children
received three doses of the oral vaccine or placebo, at 2,
4 and 6 months, with 4 to 10 weeks intervals between
doses.
Per-protocol efficacy data against G1-G4 RVGE cases
was used in the model. Based on REST data, a reduction
of 95.8%, 93.7% and 86.0% in the incidence of hospitali-
sations, ER, and GP visits respectively was assumed for
all vaccinated children. Although REST data specifically
relates to G1-G4 RVGE, the reduction in health care
utilisation due to serotypes other than G1-G4 was con-
sidered to be the same as for vaccine-contained sero-
types[16]. RotaTeq also contains P[8], a predominant
genotype and the most common P-type associated with
human RV strains in Europe and worldwide. Studies
suggest vaccines containing the serotype P[8] may pro-
tect against other G-serotypes, such as G9, which was
confirmed for RotaTeq in the REST study. G1, G2, G3,
G4 and G9 serotypes account for 98% of RVGE cases in
Spain[21].
As it was not specifically evaluated in the clinical
study, it was assumed that the vaccine efficacy for noso-
comial infections was similar to that observed for hospi-
talisation, and that for patients not seeking medical care
was similar to that observed for PCC visits.
Vaccine efficacy was considered to be nil in the 0-3
months age group, and full protection started from the
3-6 months age group.
The model took into account the waning immunity
observed in REST[20], which was a 10% decrease in vac-
cine efficacy 2 years post-vaccination. The vaccine cov-
erage rate was assumed to be 90%, based on the
observed coverage for common routine vaccinations in
Spain (diphtheria, tetanus and pertussis)[24]. The
vaccine parameters used in the model are shown in
Table 2.
Cost data
Costs were assessed from both NHS and societal per-
spectives. Costs for children who were hospitalised, or
who had ER and PCC visits were obtained from the
Spanish REVEAL study of costs[26]. Cost of nosocomial
infections was calculated based on an estimated extra
length of stay of 2.4 days and the cost per day of hospi-
talisation of €310[31]. It was assumed that 68.3% of par-
ents had to take time off work for children who were
hospitalised[25]. Costs for children not seeking medical
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Model parameters Value References
Demographics
Birth cohort size 441,283 23
Life expectancy 78.7 years 23
Mortality rate in case of no vaccination < 5 years 4/1,000 24
% of cases not seeking medical care 41.4% 29
% of G1-G2-G3-G4 97% 17
RVGE Burden (< 5 years)
Annual hospitalization incidence rate 6.5/1000 21
Age group distribution (%):
< 3 months 7.69
3-6 months 5.77
6-12 months 17.31
12-24 months 34.62
24-36 months 21.15
36-48 months 9.62
48-60 months 3.84
Annual emergency visits incidence rate 18.9/1000 21
Age group distribution (%):
< 3 months 1.0
3-6 months 16.0
6-12 months 22.0
12-24 months 46.0
24-36 months 11.0
36-48 months 3.0
48-60 months 1.0
Annual PCC visits incidence rate 21.9/1000 21
Age group distribution (%):
< 3 months 3.06
3-6 months 6.12
6-12 months 22.45
12-24 months 39.80
24-36 months 19.39
36-48 months 6.12
48-60 months 3.06
Annual nosocomial infection incidence rate 1.6/1000 25
Age group distribution (%):
< 3 months 31.85
3-6 months 16.15
6-12 months 26
12-24 months 19
24-36 months 5.5
36-48 months 1.5
48-60 months 0
Parental work days lost
(mean number of days/paediatric case)
Hospitalized RVGE case 3.12 21
RVGE case seen in emergency visit 2.02 21
RVGE case seen in PCC visit 1.37 21
RVGE nosocomial infection 1.63 Assumption based on 21, 26, 27
RVGE not seeking medical attention 0.26 Assumption based on 37
Diez-Domingo et al. BMC Public Health 2010, 10:469
http://www.biomedcentral.com/1471-2458/10/469
Page 4 of 11care were considered from the societal perspective. It
was estimated that an average of 0.26 workdays were
lost per episode not involving medical care, based on
the assumption that mothers would stop working half a
day, and taking into account that 51% of mothers work
outside their home in Spain[39]. Unit costs from local
sources[40-45] were used to value each resource. The
cost parameters used in the model are presented at
Table 3.
- Direct medical costs According to each healthcare
setting, direct medical costs for consultations, hospitali-
sations including, medication and laboratory tests were
considered. Hospitalisation costs were calculated using
DRG data (Diagnostic-Related Groups).
In Spain, the cost of consultations, hospitalisations
and laboratory tests are fully covered by the NHS. The
prescribed medication costs are shared between the
patients and the NHS based on a fixed percentage
(40% for the patients and 60% for the NHS). Over-The-
counter (OTC) drugs are not reimbursed by the NHS.
-N o n - m e d i c a lc o s t sThe non-medical costs included
transportation (car or taxi), extra nappies and baby sit-
ting; which were extracted from the REVEAL study[26].
These costs are paid by the patients.
- Indirect costs Work days lost by parents seeking med-
ical care for their child was estimated at 3.12 days for
hospitalisation, 2.02 days for emergency room visits and
1.37 days for PCC offices visits[26]. For those who did
not seek medical care the number of workdays lost was
estimated to be 0.26 days based on the assumptions that
51% of mothers work outside the home[39] and that
they stopped working for half a day to take care of their
children. The cost for one workday lost was 93.3€ based
on Eurostat data[44]. Indirect costs were included in the
societal perspective.
Model outcomes
The model was developed to compare the health out-
comes (number of RVGE cases whether or not seeking
medical care, number of hospitalisations, number of ER
and PCC visits and number of nosocomial infections)
and costs from NHS and societal perspectives for the
vaccination and not vaccination scenario.
The number needed to vaccinate (NNV) for Spain
was calculated using data from the health economic
model for a vaccinated birth cohort. This gives the
number of children to vaccinate to avoid one child
seeking medical care (hospitalisation, ER visit, PCC) due
to RVGE. The NNV was calculated following Brisson et
al [13] method which assessed the NNV to prevent
Human PapillomaVirus (HPV) related diseases. It is
defined as the reciprocal of the percentage of children
seeking medical care in the group without rotavirus vac-
cination minus the percentage in the group with rota-
virus vaccination.
- Sensitivity analyses
Since some parameters may present uncertainty, a one-
way deterministic sensitivity analyses was performed,
using 95% confidence intervals (CI) when available, data
from the literature or varying the base case value with a
fixed percentage (± 20%) when no other source could
be considered. The variables that were tested were the
vaccine coverage rate, the vaccine efficacy in reduction
of RVGE cases, the vaccine efficacy annual rate by age,
epidemiological data, costs of the disease and discount
rates (Table 4).
Results
Burden and costs of RVGE in Spain
The model estimated that each year, 181,626 children
would have an RVGE episode, resulting in 14,342 hospi-
talisations, 41,701 visits to an ER, 48,320 visits to a
PCC, 3,530 nosocomial infections and 210,404 work
Table 2 Vaccination parameters
Parameters Value Source
Coverage rate 90% 20
Vaccine efficacy (%):
Hospitalizations reduction 95.80 16
Emergency visits reduction 93.70 16
PCC visits reduction 86.00 16
Nosocomial infections
reduction
95.80 Assumption: same as
hospitalization
Cases not seeking care
reduction
86.00 Assumption: same as PCC
Waning rate after 2 years 10% Based on REST (16) and expert
opinions
Table 3 Cost per RVGE cases
Parameters NHS perspective Societal perspective Source
RVGE cases not seeking care 0 € 23.80€ Assumption based on 37, 42
Hospitalized RVGE cases 1,248.99€ 1,551.70€ 22
Emergency visit RVGE cases 204.29€ 408.87€ 22
PCC RVGE cases 16.61€ 165.89€ 22
Nosocomial infection cost 744 € 896.80€ Assumption based on 26, 27, 42
Diez-Domingo et al. BMC Public Health 2010, 10:469
http://www.biomedcentral.com/1471-2458/10/469
Page 5 of 11days lost for the parents. In addition, 73,733 cases would
not seek medical care.
T h ea n n u a lc o s t sd u et oR V G Ei nc h i l d r e nu n d e r5
years old were estimated to be €28.6 million from the
NHS perspective, while, from the societal perspective
they were estimated to be €50.0 million.
Expected health and economic benefits from a universal
rotavirus vaccination programme
The implementation of a 3-dose universal rotavirus vac-
cination programme with RotaTeq would have a positive
impact on public health in Spain since, assuming a 90%
coverage rate, the programme would prevent 136,190
episodes of RVGE annually. This would lead to the pre-
vention of 10,981 hospitalisations (-76%), 34,287 ER vis-
its (-82%), 35,187 consultations with a PCC (-73%),
2,053 nosocomial infections (-58%) and 53,692 RVGE
episodes for which no medical care is sought (-73%).
Furthermore, the programme would avoid 161,495 work
days being lost (-77%) (Table 5).
The model predicted that for every 5 infants vacci-
nated with RotaTeq, one need for medical care for
RVGE (hospitalisation, ER visit, PCC) would be avoided.
Based on the benefits of vaccination, the model pre-
dicted that the total costs associated with RVGE in a
Spanish birth cohort followed up to 5 years of age
would be reduced by €22 million for the NHS (-76.3%)
and lead to an overall reduction of €38 million from the
societal perspective (-76.5%) (Figure 2).
Sensitivity analyses
Health and economic outcomes were most sensitive to
changes in the vaccine coverage rate and health care set-
ting incidences. Benefits of a universal rotavirus vaccina-
tion programme would be increased if the vaccine
coverage was higher, which is an expected finding in the
health economic evaluations of vaccines. The same
effect would be observed with the increase in the rota-
virus incidence at any setting, the vaccine efficacy and
the costs.
Hospitalisation incidence was tested based on an
assumed 20% variation. For the higher value, the overall
number of avoided paediatric rotavirus hospitalisations
would be increased in comparison to the base case from
10,981 to 13,184 and consequently the overall avoided
paediatric RVGE costs from €22 to €25 million and
Table 4 Tested parameters for the sensitivity analyses
Parameters Base case Sensitivity analyses Source for the sensitivity
analyses
Vaccine coverage rate 90% 50%/97% Ref 50
Ratio non seeking medical care/seeking
medical care
70.65% 56.52%/84.78% ± 20%
Discount rates:
For costs 3% 6%/0% Assumption
For benefits 3% 6%/0% Assumption
Incidences:
PCC 2.19% 1.752%/2.628% ± 20%
Hospitalization 0.65% 0.52%/0.78% ± 20%
Emergency visits 1.89% 1.512%/2.268% ± 20%
Nosocomial infections 0.16% 0.128%/0.192% ± 20%
Vaccine efficacy in reduction of RVGE cases:
PCC visits 86% 73.9%/92.5% 95% CI
Emergency visits 93.7% 88.8%/96.5% 95% CI
Hospitalization 95.8% 90.5%/98.2% 95% CI
Vaccine efficacy annual rate by year Constant decrease by year of
10%
Exponential decrease after
year 2.
Assumption
Cost of the disease, NHS perspective:
PCC visit 16.61€ 14.62€/18.63€ 95% CI
Emergency visit 204.29€ 186.19€/222.39€ 95% CI
Hospitalization among non vaccinated 1248.99€ 1110.35€/1386.38€ 95% CI
Nosocomial infection 744.00€ 706.80€/781.20€ 95% CI
Cost of the disease, societal perspective:
PCC visit 165.89€ 110.81€/221.05€ 95% CI
Emergency visit 408.87€ 330.65€/486.96€ 95% CI
Hospitalization among non vaccinated 1551.70€ 1364.72€/1738.68€ 95% CI
Nosocomial infection 896.80€ 851.96€/941.64€ 95% CI
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perspectives, respectively. Work days lost by parents
were more sensitive to the variations in the incidence of
emergency visits than to variations in hospitalisations
incidence; a 20% increase in emergency visits would
result in 14,376 extra days lost in comparison to the
base case. The results of the sensitivity analyses are
shown in Table 6.
Discussion
AGE is a frequent disease, with rotavirus being the main
cause in children under 5 years of age. The burden of
RVGE is considerable both in terms of clinical and eco-
nomic considerations[6,46,47]. To our knowledge this is
the first study to estimate the burden of paediatric
RVGE, the associated direct and indirect costs, and the
potential health and economic benefits of a universal
rotavirus vaccination programme in Spain. The model
predicted that RVGE would be responsible for more
than 181,600 infections for every new birth cohort in
Spain followed up to 5 years of age and would result in
intensive use of health care services as well as more
than 210,000 work days lost by parents. The implemen-
tation of a universal vaccination programme for infants
in Spain could potentially reduce the overall clinical
burden of RVGE by 75% and save 76% of costs from
both the NHS and the societal perspectives.
We estimate that RVGE is responsible for more than
14,000 hospitalisations a year in children up to 5 years
old in Spain. This incidence is higher than that pre-
viously reported, which was 9,000 days of hospitalisation
a year in children of the same age group[3]. The differ-
ence might be explained by the methodology used since
in the previous study hospitalisation for RVGE was esti-
mated using data on laboratory reports and hospital
a d m i s s i o n sd u et oA G E .O u rd a t aw e r eb a s e do nt h e
results from a recent prospective epidemiological and
cost-of-illness study (REVEAL)[25], which included all
children aged up to 5 years old with RVGE over a one
year period in one Spanish region, so our estimation
might reflect the current burden of hospitalisations due
to RVGE in Spain.
Table 5 Base case health outcomes under the current context and under a universal rotavirus vaccination program for
a birth cohort followed until 5 years
No rotavirus vaccination
program
With rotavirus vaccination
program
Avoided cases with rotavirus
vaccination program
Reduction
(%)
RVGE cases seeking medical
care
107,894 25,380 82,514 -76.5%
Hospitalizations 14,342 3,355 10,987 -76%
Emergency visits 41,701 7,414 34,287 -82%
PCC visits 48,320 13,133 35,187 -73%
Nosocomial infections 3,530 1,477 2,053 -58%
RVGE cases not seeking
medical care
73,733 20,040 53,692 -73%
Total RVGE cases 181,626 45,420 136,206 -75%
Parental work days lost 210,404 48,909 161,495 -77%
Figure 2 RVGE economic burden in Spain with and without a universal rotavirus vaccination program.
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patients with RVGE seeking medical attention assumed
in this study based on REVEAL, is very similar to the
results in other previous studies performed in Spain
[48,35].
Furthermore a recent review of prospective studies
suggested that the total burden of symptomatic rotavirus
infection does not differ significantly between studies in
different countries around the world, even though use
of health care by infected patients does [49].
A recent study[50] in the Galician area of Spain esti-
mated that the mean indirect cost per case due to
RVGE was €428. This cost included productivity loss,
travel expenses, cost of caregivers, meals and materials.
Although our definition of indirect costs referred only
to productivity loss, our model included transportation,
Table 6 Results of the sensitivity analyses
Number of events avoided RVGE costs avoided
(M€)
RVGE cases (seeking or
nor medical care)
Hospitali-
zations
Nosocomial
infections
Emergency
visits
PCC
visits
Work
Days
Lost
NHS
perspec-
tive
Societal
perspec-
tive
BASE CASE 136,190 10,987 2,053 34,287 35,187 161,495 21.77 38.19
SENSITIVITY ANALYSES
Vaccine coverage rate
50% 75,670 6,104 1,141 19,049 19,548 89,719 12.09 21.20
97% 146,800 11,841 2,213 36,954 37,924 174,055 23.47 41.16
Ratio not seeking medical care/
seeking medical care
-20% 125,468 10,987 2,053 34,287 35,187 158,836 21.77 37.95
+20% 146,945 10,987 2,053 34,287 35,187 164,415 21.77 38.43
Cost and benefit discount rates
0%; 0% 136,207 10,987 2,053 34,287 35,187 169,052 22.84 40.02
6%; 6% 136,207 10,987 2,053 34,287 35,187 154,371 20.77 36.46
Incidences
PCC
-20% 124,197 10,987 2,053 34,287 28,150 151,082 21.66 36.96
+20% 148,216 10,987 2,053 34,287 42,225 171,908 21.88 39.41
Hospitalization
-20% 132,534 8,789 2,053 34,287 35,187 154,633 19.17 34.92
+20% 139,880 13,184 2,053 34,287 35,187 168,357 24.37 41.45
Emergency visits
-20% 125,058 10,987 2,053 27,430 35,187 147,119 20.43 35.40
+20% 147,355 10,987 2,053 41,145 35,187 175,870 23.12 40.98
Nosocomial infections
-20% 135,796 10,987 1,642 34,287 35,187 160,846 21.48 37.83
+20% 136,617 10,987 2,464 34,287 35,187 162,143 22.07 38.55
Vaccine efficacy in reduction of
RVGE cases (95% CI)
90.5%: hospitalizations, NI
88.8%: emergency visits
73.9%: PCC and home care
121,187 10,379 1,939 32,494 30,236 147,707 20.54 35.54
98.2%: hospitalizations, NI
96.5%: emergency visits
92.5%: PCC and home care
144,258 11,262 2,104 35,312 37,847 168,854 22.39 39.55
Vaccine efficacy annual rate by
age
10% decrease in year 2 and
exponential decrease until year 4.
135.507 10,891 2,051 34,208 34,987 160,770 21.65 37.99
NHS & Societal costs (95% CI)
Lower values 136,1901 10,987 2,053 34,287 35,187 161,4951 19.59 33.57
Higher values 36,190 10,987 2,053 34,287 35,187 61,495 23.94 44.64
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costs. Taking these costs together, our estimated cost is
lower, ranging form €139 to €289 (PCC and hospital
cases, respectively). The work days lost by parents
accounted for 69% and 75% of the overall cost in studies
conducted in the United States[51] and in Italy[11],
respectively, whereas in our model this was only 39% of
the overall cost of €19.6 million. This suggests that our
analysis might underestimate the real burden of RVGE
in Spain.
Although there are no other studies evaluating the
impact of a universal rotavirus vaccination in Spain, our
findings are consistent with studies performed in France
[12], UK[52] and Germany[13], that estimated that a
universal vaccination programme, with a 90% coverage,
would reduce the burden of disease by 74% to 75%.
The main objective of the study was to assess the eco-
nomic burden of rotavirus disease and to describe the
potential benefits of rotavirus vaccination, but not its
cost-effectiveness. A cost effectiveness analysis is usually
used as a decision making tool for resource allocation in
a situation of limited resources. In order to perform a
cost effectiveness analysis, a reliable vaccine price should
be considered. However, the current situation in Spain
is that the vaccine is currently available on an out-of-
pocket market, i.e., not reimbursed by the national
health system with different prices depending on the
region. It is consequently difficult to assess the current
market price. Also, the expected tender price under
reimbursement from national health system would be
lower than the current market price. Therefore, using
the current market price for the vaccine would substan-
tially unfavour the cost-effectiveness results, and even
more, results would not be reliable because of the use of
un real vaccine price.
However, a cost-effectiveness analysis would be of
interest using various price assumptions and correct
methods to assess at best the impact of uncertainty
related to rotavirus epidemiology and estimation of
quality of life in children aged under five years old on
the cost-effectiveness ratios.
As most of economic models, one limitation of this
study is that it relies on assumptions for some para-
meters which induce uncertainty around the estimates.
Due to lack of evidence, data from nearby countries was
used as proxy for Spain; this is the case for the percen-
tage of working mothers (51%[39]), which is based on
Italian data, or the percentage of cases not seeking for
medical attention (41.4%[33]), based on French informa-
tion. In both cases, differences in health behaviour
within countries might be observed; for example, it is
possible that more than 51% of mothers in Spain work
although this parameter did not have any impact in the
results. Secondly, we considered a coverage rate of 90%
as indicated by the World Health Organization (WHO)
[24] for common compulsory vaccinations. However,
according to Martin A[53], average paediatric coverage
rates might be higher in Spain (97%) due to higher
reimbursement rates from the national healthcare payer
compared with those in other European countries. This
mainly implies that our results are certainly conservative
and underestimate the real benefit of the vaccination.
Furthermore, the model did not consider additional
indirect benefits due to rotavirus vaccination pro-
gramme. For example, it is noteworthy that the epi-
demic peak of RVGE overlaps with that of other
seasonal diseases such as influenza and respiratory syn-
cytial diseases thus increasing the load for health ser-
vices which are already overcrowded at this period[6].
By decreasing substantially the number of RVGE cases,
the vaccination contributes to a better organisation of
paediatric services at hospital as well as in PCCs.
Potential herd immunity resulting from transmission
of vaccine strains has not been considered in this study.
As rotavirus is transmitted by infants and children, it
spreads within families and day care centres, the possibi-
lity of herd immunity would contribute substantially to
the burden reduction. Preliminary data from the United
States show that 2 years after the introduction of RV
vaccination into the immunization schedule, the reduc-
tion in severe rotavirus disease appears to approximate
that seen in phase III clinical trials. More over there
also been reductions in rotavirus disease in older and
unimmunised age groups[54,55]. In a recent study per-
formed in five European countries where authors were
evaluating cost -effectiveness of the rotavirus vaccina-
tion, the results show that incorporating the effect of
possible indirect protection has overall a moderate
impact on the cost-effectiveness ratio in all the coun-
tries. However, in some countries where the vaccination
is not cost-effective but near to the threshold of 30.000€
per QALY the inclusion of indirect benefits of the vac-
cine could change the overall conclusion[56]. Although
there have been reports of symptomatic cases due to
transmission of vaccine rotavirus reported among family
members, we did not take this into account due to the
lack of available data. Generally, the limitations dis-
cussed would tend to lead to an underestimation of the
vaccine benefits.
Conclusions
In conclusion, this study shows that the implementation
of a universal rotavirus vaccination program with Rota-
Teq would substantially reduce the morbidity due to
R V G Ea m o n gc h i l d r e ni nS p a i n ,a v o i d i n gm o r et h a n
136,200 cases and reducing spending by €38 million per
Diez-Domingo et al. BMC Public Health 2010, 10:469
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Page 9 of 11birth cohort. Our model could be extended to assess the
cost-effectiveness of a rotavirus vaccination program
with RotaTeq in Spain.
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